Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.
about
Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independentThe diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markersHypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapyEosinophilic myeloproliferative disordersThe lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype.Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation statusThe FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.A case of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia with a rare FIP1L1 breakpointThe Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 CasesThe serum tryptase test: an emerging robust biomarker in clinical hematology.Chronic myeloproliferative disorders: a tyrosine kinase tale.Eosinophilia: secondary, clonal and idiopathic.Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia.Imatinib mesylate in the treatment of hematologic malignancies.Erythrodermic cutaneous T cell lymphoma with hypereosinophilic syndrome: Treatment with interferon alfa and extracorporeal photopheresis.T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome.Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.Acute eosinophilic myocarditis: diagnosis and treatment.Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia.Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activitiesThe severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus.A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.Molecular analysis of PDGFRalpha/beta genes in core binding factor leukemia with eosinophilia.Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia.Concomitant FIP1L1-PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib.Leriche’s syndrome and Löffler endocarditis in a 30-year-old patient presenting with hypereosinophilic syndromeThe Spectrum of Hypereosinophilia and Associated Clonal Disorders - A Real-World Data Based on Combined Retrospective and Prospective Analysis from a Tropical Setting
P2860
Q24545984-CC69BD66-75DB-4F2A-860D-291AF145A7E5Q24675681-CB0E13E8-2386-42E2-853E-1201F63A398AQ33692709-BD25BAE3-4BCF-4C6B-8D83-065D94824CC3Q33881283-E72A6AB0-7B97-44EE-B337-99AC9D6B7756Q34447936-1C73259E-8AA1-4EED-B44B-F4D9AC5A28C8Q35575492-A2520768-0E72-4041-BEC5-567F6D5459A3Q35848279-EE487498-189B-4133-ADC6-D852F4B53496Q35855487-7E283B6C-DAEC-4B98-8369-6EC47879B2F1Q36008991-584F7530-613A-4AB9-A8FE-CBB0182F133AQ36154674-D89A9418-689B-4C7F-9B30-F26E2D04424AQ36337918-1AE018DA-BF1D-4AA0-9B24-61D51D110C7BQ36471689-AE47CDA4-ABAF-4D74-8C09-2CD93CB354AAQ36811905-C755F186-6265-4849-BC2E-FC16F28276A4Q36960525-F3B4C8CF-1499-41D4-AC9B-11BE38847F56Q36995610-FAE3E6DC-EBE9-4A4E-9F8D-A3DE64CB8413Q37334948-4E7D7E75-2EDF-4338-B76F-02820EFCCC4CQ37379320-DD6B0E1B-1D0C-4DFB-97DB-3B98B378A639Q37598944-39BF6E5D-B25F-4158-8658-D52442647598Q37702218-42FD1126-8F2E-4890-8781-958CC3CF9839Q38131481-E63ED65C-B328-49C0-B4B7-B00037752299Q41402735-08723D00-87CB-4FBF-96E8-EEEC15EF3461Q41786014-3F3AC084-7B2A-4B9C-A44C-62445D6EC765Q44527806-ABA94833-B653-4D7D-9EA9-26C4C4F0EA12Q46727966-835294CE-6664-4D99-B204-A31EEACBFF53Q46846861-08F28724-A696-4DD7-8D37-4F5BF3B6881DQ46960822-A954A8C5-69AB-4CBB-B5F5-03D497DE7E2BQ53271203-82F231E8-6C43-4C05-8766-D74EF13F9D20Q58023790-B9A1DAA6-B3E6-4B6E-BCFD-E51EF2994886Q58775557-E2D52C7F-1D5C-4433-A510-790E67C986AD
P2860
Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Molecular characterization of ...... mal conventional cytogenetics.
@en
Molecular characterization of the idiopathic hypereosinophilic syndrome
@nl
type
label
Molecular characterization of ...... mal conventional cytogenetics.
@en
Molecular characterization of the idiopathic hypereosinophilic syndrome
@nl
prefLabel
Molecular characterization of ...... mal conventional cytogenetics.
@en
Molecular characterization of the idiopathic hypereosinophilic syndrome
@nl
P2093
P2860
P50
P356
P1433
P1476
Molecular characterization of ...... rmal conventional cytogenetics
@en
P2093
Blanchet O
Gardembas M
Hachulla E
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403722
P577
2005-05-01T00:00:00Z